Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Guardant Health, Inc.GH · Entity 3238 | Chief Financial Officer | September 01, 2020 | September 03, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Guardant Health, Inc.
Report date September 01, 2020 · Filed September 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 6,373 |
Ending reported balance
After 2020-09-01 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2020-09-01 · Sale · Disposed 22,360 · Balance 14,113 F1: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $93.05 to $94.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 2 · 2020-09-01 · Sale · Disposed 4,778 · Balance 9,335 F1: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $94.06 to $95.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 3 · 2020-09-01 · Sale · Disposed 2,902 · Balance 6,433 F1: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $95.08 to $96.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 4 · 2020-09-01 · Sale · Disposed 60 · Balance 6,373 F1: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $93.05 to $94.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $94.06 to $95.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $95.08 to $96.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2020 Filed Sep 3, 2020 17:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 60 | $96.08 | $5,764.80 |
DisclosureSEC source: 0001628280-20-013293 · wf-form4_159916758358348.xml · nonDerivative · entry 4 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,373 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 17:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,902 | $95.49 | $277,119.53 |
DisclosureSEC source: 0001628280-20-013293 · wf-form4_159916758358348.xml · nonDerivative · entry 3 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,433 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $95.08 to $96.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 17:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,778 | $94.33 | $450,707.31 |
DisclosureSEC source: 0001628280-20-013293 · wf-form4_159916758358348.xml · nonDerivative · entry 2 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,335 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $94.06 to $95.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 17:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 22,360 | $93.64 | $2,093,861.95 |
DisclosureSEC source: 0001628280-20-013293 · wf-form4_159916758358348.xml · nonDerivative · entry 1 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,113 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $93.05 to $94.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 16:57 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 2,306 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001628280-20-013066 · wf-form4_159847544480654.xml · derivative · entry 8 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,445 Underlying: COMMON STOCK · 2,306 shares Expires 2028-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on August 22, 2018. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 16:57 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 7,686 | $0.00 Strike: $3.63 | $0.00 |
DisclosureSEC source: 0001628280-20-013066 · wf-form4_159847544480654.xml · derivative · entry 7 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: COMMON STOCK · 7,686 shares Expires 2026-07-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the options on July 18, 2017, thereafter vests in equal monthly installments over 36 months. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 16:57 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 440 | $96.05 | $42,260.64 |
DisclosureSEC source: 0001628280-20-013066 · wf-form4_159847544480654.xml · nonDerivative · entry 6 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,473 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $95.75 to $96.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 16:57 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 3,795 | $95.02 | $360,582.68 |
DisclosureSEC source: 0001628280-20-013066 · wf-form4_159847544480654.xml · nonDerivative · entry 5 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,913 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $94.72 to $95.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 16:57 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 3,554 | $94.34 | $335,292.89 |
DisclosureSEC source: 0001628280-20-013066 · wf-form4_159847544480654.xml · nonDerivative · entry 4 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,708 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $93.71 to $94.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 16:57 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,203 | $93.04 | $204,966.24 |
DisclosureSEC source: 0001628280-20-013066 · wf-form4_159847544480654.xml · nonDerivative · entry 3 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,262 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $92.66 to $93.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 16:57 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 2,306 | $8.80 | $20,292.80 |
DisclosureSEC source: 0001628280-20-013066 · wf-form4_159847544480654.xml · nonDerivative · entry 2 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 16:57 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 7,686 | $3.63 | $27,900.18 |
DisclosureSEC source: 0001628280-20-013066 · wf-form4_159847544480654.xml · nonDerivative · entry 1 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 17:37 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,860 | $89.38 | $255,634.24 |
DisclosureSEC source: 0001628280-20-012889 · wf-form4_159787301624357.xml · nonDerivative · entry 5 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,473 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $89.10 to $89.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 17:37 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 8,673 | $88.55 | $767,968.13 |
DisclosureSEC source: 0001628280-20-012889 · wf-form4_159787301624357.xml · nonDerivative · entry 4 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,333 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $88.10 to $89.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 17:37 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 6,218 | $87.38 | $543,334.44 |
DisclosureSEC source: 0001628280-20-012889 · wf-form4_159787301624357.xml · nonDerivative · entry 3 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,006 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $87.085 to $88.065, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 17:37 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 6,136 | $86.72 | $532,129.87 |
DisclosureSEC source: 0001628280-20-012889 · wf-form4_159787301624357.xml · nonDerivative · entry 2 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,224 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $86.07 to $87.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 17:37 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,113 | $85.30 | $94,938.79 |
DisclosureSEC source: 0001628280-20-012889 · wf-form4_159787301624357.xml · nonDerivative · entry 1 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,360 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $84.92 to $85.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 01, 2020 Filed Aug 4, 2020 17:37 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCOMMON STOCK | 714 | $85.18 | $60,818.52 |
DisclosureSEC source: 0001628280-20-011672 · wf-form4_159657691434093.xml · nonDerivative · entry 1 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,473 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| May 22, 2020 Filed May 26, 2020 17:17 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 1,537 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001628280-20-008424 · wf-form4_159052781513744.xml · derivative · entry 7 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,751 Underlying: COMMON STOCK · 1,537 shares Expires 2028-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on August 22, 2018. Read SEC document |
| May 22, 2020 Filed May 26, 2020 17:17 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 7,685 | $0.00 Strike: $3.63 | $0.00 |
DisclosureSEC source: 0001628280-20-008424 · wf-form4_159052781513744.xml · derivative · entry 6 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,686 Underlying: COMMON STOCK · 7,685 shares Expires 2026-07-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the options on July 18, 2017, thereafter vests in equal monthly installments over 36 months. Read SEC document |
| May 22, 2020 Filed May 26, 2020 17:17 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,144 | $97.00 | $110,972.00 |
DisclosureSEC source: 0001628280-20-008424 · wf-form4_159052781513744.xml · nonDerivative · entry 5 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,187 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $96.97 to $97.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 22, 2020 Filed May 26, 2020 17:17 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 6,960 | $96.77 | $673,542.17 |
DisclosureSEC source: 0001628280-20-008424 · wf-form4_159052781513744.xml · nonDerivative · entry 4 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,331 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $95.97 to $96.955, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 22, 2020 Filed May 26, 2020 17:17 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,118 | $95.38 | $106,631.60 |
DisclosureSEC source: 0001628280-20-008424 · wf-form4_159052781513744.xml · nonDerivative · entry 3 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,291 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $94.87 to $95.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 22, 2020 Filed May 26, 2020 17:17 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 1,537 | $8.80 | $13,525.60 |
DisclosureSEC source: 0001628280-20-008424 · wf-form4_159052781513744.xml · nonDerivative · entry 2 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2020 Filed May 26, 2020 17:17 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 7,685 | $3.63 | $27,896.55 |
DisclosureSEC source: 0001628280-20-008424 · wf-form4_159052781513744.xml · nonDerivative · entry 1 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2020 Filed May 12, 2020 17:02 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 129 | $95.31 | $12,294.35 |
DisclosureSEC source: 0001628280-20-007585 · wf-form4_158931735745024.xml · nonDerivative · entry 7 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,187 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 11, 2020 Filed May 12, 2020 17:02 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 5,255 | $94.88 | $498,602.81 |
DisclosureSEC source: 0001628280-20-007585 · wf-form4_158931735745024.xml · nonDerivative · entry 6 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,316 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $94.285 to $95.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 11, 2020 Filed May 12, 2020 17:02 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,796 | $93.59 | $448,867.23 |
DisclosureSEC source: 0001628280-20-007585 · wf-form4_158931735745024.xml · nonDerivative · entry 5 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,571 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $93.21 to $94.185, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 11, 2020 Filed May 12, 2020 17:02 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,096 | $92.67 | $101,570.16 |
DisclosureSEC source: 0001628280-20-007585 · wf-form4_158931735745024.xml · nonDerivative · entry 4 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,367 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $92.14 to $93.115, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 11, 2020 Filed May 12, 2020 17:02 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 3,716 | $91.40 | $339,633.11 |
DisclosureSEC source: 0001628280-20-007585 · wf-form4_158931735745024.xml · nonDerivative · entry 3 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,463 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $91.05 to $92.025, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 11, 2020 Filed May 12, 2020 17:02 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 6,870 | $90.53 | $621,923.24 |
DisclosureSEC source: 0001628280-20-007585 · wf-form4_158931735745024.xml · nonDerivative · entry 2 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,179 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $90.005 to $91.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 08, 2020 Filed May 12, 2020 17:02 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 913 | $90.40 | $82,533.28 |
DisclosureSEC source: 0001628280-20-007585 · wf-form4_158931735745024.xml · nonDerivative · entry 1 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,049 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $90.21 to $90.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 24, 2020 Filed Mar 25, 2020 17:13 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 114 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001628280-20-004062 · wf-form4_158517079737920.xml · derivative · entry 14 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,288 Underlying: COMMON STOCK · 114 shares Expires 2028-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on August 22, 2018. Read SEC document |
| March 24, 2020 Filed Mar 25, 2020 17:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 19 | $66.59 | $1,265.16 |
DisclosureSEC source: 0001628280-20-004062 · wf-form4_158517079737920.xml · nonDerivative · entry 11 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,962 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $66.24 to $66.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 24, 2020 Filed Mar 25, 2020 17:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 65 | $65.57 | $4,261.78 |
DisclosureSEC source: 0001628280-20-004062 · wf-form4_158517079737920.xml · nonDerivative · entry 10 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,981 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $65.11 to $66.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 24, 2020 Filed Mar 25, 2020 17:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 18 | $64.27 | $1,156.89 |
DisclosureSEC source: 0001628280-20-004062 · wf-form4_158517079737920.xml · nonDerivative · entry 9 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,046 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $63.83 to $64.775, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 24, 2020 Filed Mar 25, 2020 17:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 12 | $61.55 | $738.64 |
DisclosureSEC source: 0001628280-20-004062 · wf-form4_158517079737920.xml · nonDerivative · entry 8 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,064 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $61.32 to $61.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 24, 2020 Filed Mar 25, 2020 17:13 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 114 | $8.80 | $1,003.20 |
DisclosureSEC source: 0001628280-20-004062 · wf-form4_158517079737920.xml · nonDerivative · entry 7 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,076 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 17:13 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 3,729 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001628280-20-004062 · wf-form4_158517079737920.xml · derivative · entry 13 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,402 Underlying: COMMON STOCK · 3,729 shares Expires 2028-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on August 22, 2018. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 17:13 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 15,371 | $0.00 Strike: $3.63 | $0.00 |
DisclosureSEC source: 0001628280-20-004062 · wf-form4_158517079737920.xml · derivative · entry 12 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,371 Underlying: COMMON STOCK · 15,371 shares Expires 2026-07-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the options on July 18, 2017, thereafter vests in equal monthly installments over 36 months. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 17:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 190 | $64.00 | $12,160.00 |
DisclosureSEC source: 0001628280-20-004062 · wf-form4_158517079737920.xml · nonDerivative · entry 6 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,962 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 17:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 680 | $62.45 | $42,466.75 |
DisclosureSEC source: 0001628280-20-004062 · wf-form4_158517079737920.xml · nonDerivative · entry 5 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,152 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $62.05 to $62.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 17:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 3,985 | $61.36 | $244,525.18 |
DisclosureSEC source: 0001628280-20-004062 · wf-form4_158517079737920.xml · nonDerivative · entry 4 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,832 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $61.02 to $62.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 17:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 14,245 | $60.32 | $859,281.19 |
DisclosureSEC source: 0001628280-20-004062 · wf-form4_158517079737920.xml · nonDerivative · entry 3 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,817 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $60.00 to $60.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 17:13 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 3,729 | $8.80 | $32,815.20 |
DisclosureSEC source: 0001628280-20-004062 · wf-form4_158517079737920.xml · nonDerivative · entry 2 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 17:13 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 15,371 | $3.63 | $55,796.73 |
DisclosureSEC source: 0001628280-20-004062 · wf-form4_158517079737920.xml · nonDerivative · entry 1 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 17:56 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 10,759 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001628280-19-014367 · wf-form4_157429055431721.xml · derivative · entry 6 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,131 Underlying: COMMON STOCK · 10,759 shares Expires 2028-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on August 22, 2018. Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 17:56 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 14,722 | $0.00 Strike: $3.63 | $0.00 |
DisclosureSEC source: 0001628280-19-014367 · wf-form4_157429055431721.xml · derivative · entry 5 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,742 Underlying: COMMON STOCK · 14,722 shares Expires 2026-07-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the options on July 18, 2017, thereafter vests in equal monthly installments over 36 months. Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 17:56 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 12,936 | $79.90 | $1,033,586.40 |
DisclosureSEC source: 0001628280-19-014367 · wf-form4_157429055431721.xml · nonDerivative · entry 4 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,962 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $3.63 or $8.80 per share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.68 to $80.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 17:56 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 12,545 | $79.25 | $994,191.25 |
DisclosureSEC source: 0001628280-19-014367 · wf-form4_157429055431721.xml · nonDerivative · entry 3 BERTOCCI DEREK A · CIK 0001206964 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,898 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $3.63 or $8.80 per share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.66 to $79.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.